Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Adial Pharmaceuticals, Inc. WT EXP 073123 ADILW
$0.05
+$0.09 (178.29%)
На 18:02, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
0.00000000
-
week52high
0.02
-
week52low
0.02
-
Revenue
0
-
P/E TTM
0
-
Beta
0.00000000
-
EPS
0.00000000
-
Last Dividend
0.00000000
-
Next Earnings Date
07 мая 2023 г. в 03:36
Описание компании
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Stilley William B. III | D | 1020979 | 166667 | 30 дек 2022 г. |
| Claiborne Cary J | A | 1100000 | 75000 | 20 сент 2022 г. |
| Claiborne Cary J | A | 1025000 | 25000 | 19 сент 2022 г. |
| Stilley William B. III | A | 100000 | 100000 | 22 авг 2022 г. |
| Claiborne Cary J | A | 1000000 | 1000000 | 18 авг 2022 г. |
| Goodman Tony | A | 25000 | 25000 | 27 июн 2022 г. |
| Johnson Bankole A. | A | 35000 | 35000 | 23 февр 2022 г. |
| Goodman Tony | A | 40000 | 40000 | 23 февр 2022 г. |
| Truluck Joseph | A | 100000 | 100000 | 23 февр 2022 г. |
| Stilley William B. III | A | 1187646 | 250000 | 23 февр 2022 г. |
Новостная лента
Adial Pharmaceuticals Announces Third-Party Sales and Distribution Agreement with Brik for Rapid Result COVID-19 Antibody Test Kits
Yahoo
06 авг 2020 г. в 13:30
CHARLOTTESVILLE, VA / ACCESSWIRE / August 6, 2020 / Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals Schedules Business and Clinical Update Conference Call
Yahoo
28 июл 2020 г. в 13:30
Developments to be Shared by Dr.
Adial Pharmaceuticals Receives European Medicines Agency (EMA) Agreement on the Pediatric Investigation Plan (PIP) for AD04 in Alcohol Use Disorder
Yahoo
22 июл 2020 г. в 13:45
EMA Agreement paves the way for a marketing authorization in Europe after Phase 3CHARLOTTESVILLE, VA / ACCESSWIRE / July 22, 2020 / Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals Announces Approval to Commence Landmark ONWARD(TM) Pivotal Phase 3 Trial in Sweden and Estonia
Yahoo
06 июл 2020 г. в 12:15
CHARLOTTESVILLE, VA / ACCESSWIRE / July 6, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL:ADILW) ("Adial"), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has received approvals in Sweden and Estonia to commence the Company's landmark ONWARD™ pivotal Phase 3 clinical trial to investigate its lead drug candidate, AD04, as a therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in persons with certain target genotypes related to the serotonin transporter and receptor genes. The Swedish Medical Products Agency and Swedish Ethical Review Authority have provided approval for ONWARD™ to commence in Sweden; and the Estonian State Agency of Medicines and Ethics Review Committee overseeing human trials granted approval to commence ONWARD™ in Estonia.
Adial Pharmaceuticals Announces Commencement of Landmark ONWARD(TM) Pivotal Phase 3 Trial in Poland
Yahoo
25 июн 2020 г. в 13:30
CHARLOTTESVILLE, VA / ACCESSWIRE / June 25, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial"), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has commenced its landmark ONWARD™ pivotal Phase 3 clinical trial in Poland to investigate its lead drug candidate, AD04, as a therapeutic agent for the treatment of Alcohol Use Disorder in persons with certain target genotypes related to the serotonin transporter and receptor genes. "We are pleased to announce we were able to begin the trial less than two weeks after we received approval from Poland's Office for Registration of Medicinal Products, Medical Devices and Biocidal Products and the relevant regional Polish ethics committees overseeing the trial," commented William Stilley, Chief Executive Officer of Adial Pharmaceuticals.